Skip to main content
S&P 5007,703.04+1.77%DOW53,353.70+3.03%NASDAQ25,831.67+1.81%BTC$80,129.00+3.41%ETH$2,417.22+5.71%GOLD$4,071.20+3.32%OIL$88.24-8.17%
Smart Investors Daily
SID Premium
WX

OTC · WXXWY

WuXi Biologics (Cayman) Inc.

Healthcare · Biotechnology

$12.50

Up+$1.50 (+13.67%)

Updated Nov 4, 2026, 7:30 PM

SID Score

5.5/10

Composite research score

Smart Money

46/100

Neutral

Market cap
17.21B
P/E ratio
30.57
Dividend yield
0.00%
52-week range
— – —
Volume
10.32K
Avg. volume
37.66K

Price performance · WXXWY

WXXWY price history

1M range · 0 trading sessions · Daily adjusted prices

WXXWY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest WXXWY news

The latest Smart Investors Daily articles mentioning WXXWY.

Stock researchCompany · Overview

WXXWY research

Overview

Company profile and research snapshot.

Company profile

WUXI BIOLOGICS UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$10.10
Implied upside
—
Analysts
33
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it received the top-honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026, as well as the Best in Transition (Hong Kong) award. WuXi Biologics is the only pharmaceutical company among this year's Jade Award recipients.

Yahoo · Oct 20, 2026

Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?

WuXi Biologics (Cayman) has seen a sharp swing in investor fortunes over the past few years, which puts fresh focus on whether the current share price lines up with the cash the business can generate. After such a mixed journey, the key issue is how today’s valuation stacks up against the company’s own cash flow profile rather than its past share-price highs. Over 5 years the stock has fallen 58.3%, which puts previous expectations under the microscope and raises the question of what its...

Yahoo · Oct 14, 2026

WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that the Company has continued to be included in multiple Hang Seng sustainability indexes — notably the Hang Seng ESG 50 Index and the Hang Seng Corporate Sustainability Benchmark Index —once again demonstrating its excellence in environmental, social and governance (ESG) performance.

Yahoo · Oct 1, 2026

Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030 The global recombinant proteins manufacturing services m

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By